Drug-Coated Balloon for De Novo Coronary Artery Disease

Kirtane, 2009, Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies, Circulation, 119, 3198, 10.1161/CIRCULATIONAHA.108.826479 Neumann, 2019, 2018 ESC/EACTS guidelines on myocardial revascularization, Eur Heart J, 40, 87, 10.1093/eurheartj/ehy394 Waksman, 2009, Drug-eluting balloon: the comeback kid?, Circ Cardiovasc Interv, 2, 352, 10.1161/CIRCINTERVENTIONS.109.873703 Axel, 1997, Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery, Circulation, 96, 636, 10.1161/01.CIR.96.2.636 Cortese, 2010, Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study, Heart, 96, 1291, 10.1136/hrt.2010.195057 Jeger, 2018, Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial, Lancet, 392, 849, 10.1016/S0140-6736(18)31719-7 Latib, 2012, A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study, J Am Coll Cardiol, 60, 2473, 10.1016/j.jacc.2012.09.020 Tang, 2018, Drug-coated balloon versus drug-eluting stent for small-vessel disease: the RESTORE SVD China randomized trial, J Am Coll Cardiol Intv, 11, 2381, 10.1016/j.jcin.2018.09.009 Vos, 2019, Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial, J Am Coll Cardiol Intv, 12, 1691, 10.1016/j.jcin.2019.04.016 Gobic, 2017, Drug-coated balloon versus drug-eluting stent in primary percutaneous coronary intervention: a feasibility study, Am J Med Sci, 354, 553, 10.1016/j.amjms.2017.07.005 Nishiyama, 2016, Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease, Int J Cardiol, 222, 113, 10.1016/j.ijcard.2016.07.156 Siontis, 2016, Percutaneous coronary interventions for the treatment of stenoses in small coronary arteries: a network meta-analysis, J Am Coll Cardiol Intv, 9, 1324, 10.1016/j.jcin.2016.03.025 Naganuma, 2015, A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study, Int J Cardiol, 184, 17, 10.1016/j.ijcard.2015.01.080 Latib, 2015, 3-Year follow-up of the Balloon Elution and Late Loss Optimization Study (BELLO), J Am Coll Cardiol Intv, 8, 1132, 10.1016/j.jcin.2015.04.008 Sinaga, 2016, Drug-coated balloons: a safe and effective alternative to drug-eluting stents in small vessel coronary artery disease, J Intervent Cardiol, 29, 454, 10.1111/joic.12333 Sim, 2018, Treatment of very small de novo coronary artery disease with 2.0 mm drug-coated balloons showed 1-year clinical outcome comparable with 2.0 mm drug-eluting stents, J Invasive Cardiology, 30, 256 McKeown, 2019 Radke, 2011, Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients, EuroIntervention, 7, 730, 10.4244/EIJV7I6A116 Kleber, 2013, Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group, Clin Res Cardiol, 102, 785, 10.1007/s00392-013-0609-7 Belkacemi, 2012, J Am Coll Cardiol, 59, 2327, 10.1016/j.jacc.2012.02.027 Herdeg, 2009, Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation, Circ Cardiovasc Interv, 2, 294, 10.1161/CIRCINTERVENTIONS.108.827865.108.827865 Poss, 2010, Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis, Clin Res Cardiol, 99, 411, 10.1007/s00392-010-0176-0 Ali, 2011, Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus, EuroIntervention, 7, K83, 10.4244/EIJV7SKA15 Fischer, 2012, Paclitaxel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study, EuroIntervention, 8, 450, 10.4244/EIJV8I4A71 Liistro, 2013, Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial, Am Heart J, 166, 920, 10.1016/j.ahj.2013.08.023 Chae, 2017, Comparison of drug-eluting balloon followed by bare metal stent with drug-eluting stent for treatment of de novo lesions: randomized, controlled, single-center clinical trial, J Korean Med Sci, 32, 933, 10.3346/jkms.2017.32.6.933 Zurakowski, 2015, Stenting and adjunctive delivery of paclitaxel via balloon coating versus durable polymeric matrix for de novo coronary lesions: clinical and angiographic results from the prospective randomized trial, J Interv Cardiol, 28, 348, 10.1111/joic.12210 Clever, 2014, Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent, Catheter Cardiovasc Interv, 84, 323, 10.1002/ccd.25184 Poerner, 2014, Stent coverage and neointimal proliferation in bare metal stents postdilated with a paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up, Circ Cardiovasc Interv, 7, 760, 10.1161/CIRCINTERVENTIONS.113.001146 Werner, 2018, Complex PCI procedures: challenges for the interventional cardiologist, Clin Res Cardiol, 107, 64, 10.1007/s00392-018-1316-1 Stella, 2012, Catheter Cardiovasc Interv, 80, 1138, 10.1002/ccd.23499 Lopez Minguez, 2014, A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results, EuroIntervention, 10, 50, 10.4244/EIJV10I1A10 Unverdorben, 2013, Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?, EuroIntervention, 9, 620, 10.4244/EIJV9I5A99 Burzotta, 2016, Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial, Heart Vessels, 31, 677, 10.1007/s00380-015-0671-3 Garcia-Touchard, 2017, A randomised trial of Paclitaxel-Eluting Balloon After Bare Metal Stent Implantation vs. Bare Metal Stent in ST-Elevation Myocardial Infarction (the PEBSI study), EuroIntervention, 12, 1587, 10.4244/EIJ-D-16-00128 Seeger, 2016, Paclitaxel-coated balloon plus bare-metal stent for de-novo coronary artery disease: final 5-year results of a randomized prospective multicenter trial, Coron Artery Dis, 27, 84, 10.1097/MCA.0000000000000314 Rissanen, 2019, Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial, Lancet, 394, 230, 10.1016/S0140-6736(19)31126-2 Besic, 2015, Drug-eluting balloons in patients with non-ST elevation acute coronary syndrome, J Cardiol, 65, 203 Shin, 2019, Prospective randomized trial of paclitaxel-coated balloon versus bare-metal stent in high bleeding risk patients with de novo coronary artery lesions, Coron Artery Dis, 30, 425, 10.1097/MCA.0000000000000755 Saito, 2019, BIOFLOW IV, a randomized, intercontinental, multicenter study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months, EuroIntervention, 15, e1006, 10.4244/EIJ-D-18-01214 Costopoulos, 2013, The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease, J Am Coll Cardiol Intv, 6, 1153, 10.1016/j.jcin.2013.07.005 Ielasi, 2016, Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the “no more metallic cages” multicentre pilot experience, EuroIntervention, 11, e1589, 10.4244/EIJV11I14A309 Dangas, 2013, J Am Coll Cardiol Intv, 6, 914, 10.1016/j.jcin.2013.05.005 Jim, 2016, Angiographic result of sirolimus-eluting balloon in de novo small coronary artery lesion (ARSENAL), Int J Cardiol, 222, 992, 10.1016/j.ijcard.2016.08.133 Cortese, 2019, Angiographic performance of a novel sirolimus-coated balloon in native coronary lesions: the FAtebenefratelli SIrolimus COated NATIVES prospective registry, J Cardiovasc Med (Hagerstown), 20, 471, 10.2459/JCM.0000000000000806 Cortese, 2017, Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FAtebenefratelli SIrolimus COated-balloon (FASICO) registry, Cardiovasc Revasc Med, 18, 487, 10.1016/j.carrev.2017.03.025 Katsanos, 2018, Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials, J Am Heart Assoc, 7 Giacoppo, 2019, Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study), Eur Heart J Poerner, 2017, Fractional flow reserve-guided coronary angioplasty using paclitaxel-coated balloons without stent implantation: feasibility, safety and 6-month results by angiography and optical coherence tomography, Clin Res Cardiol, 106, 18, 10.1007/s00392-016-1019-4 Ann, 2016, Anatomical and physiological changes after paclitaxel-coated balloon for atherosclerotic de novo coronary lesions: serial IVUS-VH and FFR study, PLoS One, 11, 10.1371/journal.pone.0147057